1209 Global Metabolic Characterization Reveals Unique Metabolic Profiles of Tumor Tissue and Plasma in Patients With IDH Wildtype and IDH Mutant Gliomas

View at publisher Summarise with VIRAT
Authors: Joseph Garcia, Zachary Charles Gersey, Stephanie M. Casillo, Oliver Young Tang, Pascal N. Zinn, Kalil G. Abdullah, Sameer Agnihotri
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Gliomas are the most common primary brain tumors in adults and are classified by the WHO into molecularly and histologically defined subtypes. Grade IV glioblastomas carry a dismal prognosis, with median survival just over one year, whereas low-grade gliomas (LGGs, Grades II and III) have relatively favorable outcomes. The differences in clinical behavior between high-grade gliomas (HGGs), LGGs, and normal brain are reflected in their underlying molecular and metabolic profiles. High-throughput approaches like global metabolomics can uncover metabolic differences in gliomas that are not captured by genomics or histology. These insights may guide diagnostics and reveal therapeutic targets. As leaders in both patient care and specimen collection, neurosurgeons are at the forefront of integrating metabolic profiling into clinical workflows and driving translational research in neuro-oncology. METHODS: Matched tumor tissue and plasma were collected from glioma patients and normal controls. A total of 96 samples underwent global, untargeted metabolomics and complex lipid profiling to assess metabolic pathways distinguishing glioma subtypes and plasma biomarkers. RESULTS: Compared to IDH mutant tumors, IDH WT HGGs showed upregulation in taurine/hypotaurine metabolism, cysteine/methionine metabolism, and nicotinate/nicotinamide metabolism. Relative to LGGs, HGGs exhibited elevated glycolysis, gluconeogenesis, and enhanced glutamine, glutamate, and glutathione metabolism. Both WT and mutant tumors showed increased glucose and fatty acid utilization compared to normal brain. Lipid profiling revealed triacylglycerol accumulation in WT tumors and cholesterol ester elevation in both WT and mutant tumors. Plasma from LGG patients had higher levels of phospholipids and sphingolipids compared to healthy controls. As expected, 2-hydroxyglutarate was elevated in IDH mutant tumors. CONCLUSIONS: IDH WT HGGs harbor a distinct metabolic profile, separable from IDH mutant and low-grade gliomas. Furthermore, glioma-associated metabolic changes are reflected in plasma, suggesting potential for non-invasive diagnostics. These data lay the groundwork for leveraging metabolic phenotyping in precision neurosurgical care and therapeutic development.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Metabolomics and Mass Spectrometry Studies Cancer Hypoxia and Metabolism

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
237–237
Publication date
26 March 2026
Language
EN